“Vertex Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Vertex Pharmaceutical. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in phase-I.
The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.
“Vertex Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.
1. Vertex Pharmaceutical
1.1 Business Overview
1.2 Vertex Pharmaceutical Cancer Pipeline Overview
2. Vertex Pharmaceutical Cancer Drugs in Phase-I
2.1 VX 984
2.2 VX 803
2.3 MK 5108
2.4 MAPK1 Inhibitors – Vertex
3. Vertex Pharmaceutical Cancer Drugs in Phase-I/II
4. Vertex Pharmaceutical Cancer Drugs in Phase-II
4.1 VX 970
5. Discontinued in Cancer Drugs in Clinical Pipeline
5.1 AVN 944
5.5 MK 6592
5.6 VG 18563
5.7 Protein Kinase Inhibitors - Novartis/Vertex
5.8 Aurora Kinase Inhibitors - Vertex/Novartis
Figure 1-1: Vertex Pharmaceutical Cancer Pipeline by Phase (%)
Figure 1-2: Vertex Pharmaceutical Cancer Pipeline by Phase (Number)